Document is current
Any future updates will be listed below
-
Authors
Zhang, Fangming
Hu, Zhijian
Jacob, Asha
Brenner, Max
Wang, Ping
-
Funding
Funding for this research was provided by:
National Institute of Health, United States (R43 DK120175, R01 HL076179, R01 HL076179, R43 DK120175, R01 HL076179)
- License Information
-
More Information
Article History
Received: 22 November 2024
Accepted: 7 January 2025
First Online: 10 January 2025
Declarations
:
: All animal experiments were performed based on the NIH Guide and Care of Laboratory Animals and were approved by the Institutional Animal Care and Use Committee of the Feinstein Institutes for Medical Research.
: All authors have read and provided consent for publication of this study.
: PW is the inventor of a patent entitled “Peptides inhibiting cold-inducible RNA binding protein activity”. PW was a co-founder of TheraSource LLC, which had an exclusive option to license the relevant technology. FZ, and MB were part-time employees of TheraSource LLC when the study was conducted. ZH and AJ declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
